Why Alnylam Pharmaceuticals, Inc. (ALNY) stock moved
Alnylam Pharmaceuticals, Inc. (ALNY) shares tumbled 6.3% to $231.18 as of October 1, 2026, a significant decline from the prior close of $246.74. BestStocks flagged the session as a major change for ALNY. The move is tied to price move down. Below, we break down what changed for ALNY, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
ALNY fell 6.3% to $231.18
Alnylam Pharmaceuticals, Inc. (ALNY) moved -6.86% from $248.21 to $231.18 on October 1, 2026. JPMorgan trimmed its price target on the stock and warned that near-term results could face friction. The decline was also driven by pipeline scrutiny—recent updates on Huntington's disease programs highlighted ongoing hurdles in proving efficacy in smaller patient cohorts—and lingering commercial concerns about how quickly flagship drug Amvuttra can scale past initial pent-up demand. ALNY earnings are scheduled for October 29, 2026, with consensus EPS estimate of $1.77; also monitor for ALN-HTT02 Huntington's disease data updates.
What it means for Alnylam Pharmaceuticals, Inc. investors
For Alnylam Pharmaceuticals, Inc. investors, the recent signals add up to a strong bearish shift. On the constructive side: Positive price momentum; Positive price momentum. Weighing against that: Material negative event; Sharp 6.3% decline — elevated risk. Wall Street's consensus price target sits at $347.33, implying +50.2% upside from $231.18. Over the past 90 days analysts logged 1 upgrade and 0 downgrades. BestStocks rates the overall signal quality medium (60/100). With earnings roughly 28 days out, the next report is the most likely near-term test of the move.
ALNY price reaction
ALNY last traded at $231.18, down $15.56 (-6.31%) from the previous close of $246.74. The session traded on 1.2× average volume (normal), so participation was unremarkable. Over the past month the stock has ranged between $231.18 and $267.40, and it currently sits about 0% of the way up that band.
Bullish and bearish analyst opinions on Alnylam Pharmaceuticals, Inc. (ALNY)
The consensus analyst price target on Alnylam Pharmaceuticals, Inc. (ALNY) is $347.33, 50.2% above the recent $231.18. Over the past 90 days analysts logged 1 upgrade, 23 maintains, and 0 downgrades. Here is how the bullish and bearish cases on ALNY line up.
The bullish case
- Wall Street's consensus price target of $347.33 implies +50.2% upside from $231.18.
- The Street's most bullish target is $455.00 (+96.8%).
- 1 analyst upgrade in the past 90 days, most recently Raymond James to Strong Buy (2026-08-03).
- Positive price momentum.
The bearish case
- Material negative event.
- Sharp 6.3% decline — elevated risk.
- Alnylam Pharmaceuticals plummeted 27.66% to $207.34 following an earnings report and material event filing (8-K) released today.
Weighing both sides, BestStocks' composite read of recent signals is strongly bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Oct 1, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for ALNY
In-depth ALNY event analyses
Frequently asked questions about ALNY
Why did Alnylam Pharmaceuticals, Inc. (ALNY) stock move?
ALNY tumbled 6.3% to $231.18. The move is associated with price move down.
How much did ALNY stock fall?
ALNY lost 6.31% ($15.56) versus the prior close of $246.74, last trading at $231.18 on 1.2× average volume.
When is Alnylam Pharmaceuticals, Inc.'s next earnings date?
ALNY's next earnings report is estimated for 2026-10-29 — about 28 days away.
What is the analyst price target for ALNY?
The consensus analyst price target for ALNY is $347.33, about 50.2% above the current $231.18. Over the past 90 days, analysts recorded 1 upgrade, 23 maintains, and 0 downgrades.
How BestStocks tracks ALNY
This page is generated automatically by BestStocks' change-detection system after price move down was detected and verified against independent data sources. It draws on 20 tracked change events for ALNY, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of October 1, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.